Clinical trials: Esophagus Cancer
Stomach Cancer Stage IV, Esophagus Cancer
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
- Conditions
- Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
- Trial name
- NCT07070466
- Testing
- Ivonescimab, 5-Fluorouracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002631
- Testing
- chemotherapy, cisplatin, fluorouracil
- Where
- 18 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Neoplasms
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate
- Trial name
- NCT03787251
- Testing
- Apatinib, The chemotherapeutic drug chosen by the investigator.
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Barrett's Esophagus
Ramanspectroscopy in Barrett's Esophagus
This study is being done to see if a new device, called near-infrared Raman spectroscopy, can provide similar information as that obtained from taking biopsies of the lining of your Barrett's esophagus
- Trial name
- NCT00588575
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Mayo Clinic
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer.
- Trial name
- HCHTOG1903 (NCT04138212)
- Testing
- Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer, Esophageal Cancer
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
This is a nonrandomized, open-label, single group assignment, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing regimen of Oraxol in combination with ramucirumab.
- Conditions
- Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
- Trial name
- NCT02970539
- Testing
- Oraxol, Ramucirumab
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.
Esophagus Cancer, Lung Cancer
Imaging Study Compare 4DCT Image
The goal of this clinical research study is to learn about ways to possibly reduce scanning errors when using 4-dimensional computed tomography (4D CT) scans to check lung function in patients with esophageal or lung cancer.
- Trial name
- NCT01626001
- Testing
- 4D CT scans
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Cancer
Effects of a "Walk, Eat, & Breathe" Nursing Intervention For Patients With Esophageal Cancer
The purpose of this stratified randomized controlled trial (RCT) is to test the effects of Walk, Eat, \& Breathe on preserving patients' nutritional status, functional walking capacity, pulmonary function, and emotional…
- Trial name
- NCT02850172
- Testing
- Walk, Eat, & Breathe
- Where
- Taiwan
- Volunteers
- 144 people
- Sponsor
- National Taiwan University Hospital
Barrett Esophagus
Pilot Study for OCT Guided In Vivo Laser Capture Microdissection for Assessing the Prognosis of Barrett's Esophagus
The investigators have developed a new technology, termed in-vivo laser capture microdissection (IVLCM), that addresses the limitations of endoscopic biopsy for screening for BE and provides targeted genomic profiling of aberrant…
- Trial name
- IVLCM (NCT03830801)
- Testing
- IVLCM tethered capsule
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Esophageal Cancer
Non-endoscopic EC Screening Program in Northern Iran
The aim of this study is to assess the effects of implementation of a non-endoscopic esophageal cancer-screening program on outcomes of interest in an asymptomatic high-risk population in Golestan Province, Iran.
- Trial name
- NESP (NCT02311712)
- Testing
- Capsule sponge
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Gastroesophageal Reflux Disease, Barrett's Esophagus
Survey Study on Barrett's Esophagus Screening
The goal of this study is to optimize Barrett's Esophagus (BE) screening to reduce the incidence, morbidity, and mortality of Esophageal Adenocarcinoma (EAC).
- Conditions
- Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
- Trial name
- SCREEN-BE (NCT04408105)
- Testing
- Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey
- Where
- 7 sites in United States
- Volunteers
- 725 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Esophageal Cancer
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
China is a country with a large incidence of esophageal cancer. The prevalence and mortality rate of esophageal cancer in China ranks fifth in the world.
- Trial name
- NCT04390945
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
P53 Mutation in Esophageal Cancer
ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance
Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death…
- Trial name
- NCT07722819
- Testing
- No intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ling Zhiqiang
Superficial Esophageal Cancer
A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
The purpose of this study is to evaluate the efficacy and safety of esophageal epithelial regenerative treatment by the transplantation of the product, CLS2702C, to the esophageal wound site after extensive ESD for superficial…
- Trial name
- NCT04689594
- Testing
- CLS2702C/CLS2702D
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- CellSeed Inc.
Kidney Cancer, Head and Neck Cancer
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT00967577
- Testing
- 177Lu-J591
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Melanoma, NSCLC
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for…
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer
- Trial name
- NCT04114136
- Testing
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dan Zandberg